Adam N. Rosenthal

ORCID: 0000-0001-6924-0721 · 6 papers in corpus
other 2023
Journal of medical genetics ·doi:10.1136/jmg-2022-108741

BACKGROUND: Our study aimed to establish 'real-world' performance and cost-effectiveness of ovarian cancer (OC) surveillance in women with pathogenic germline BRCA1/2 variants who defer risk-reducing bilateral salpingo-oophorectomy (RRSO). …

guideline 2023
Journal of medical genetics ·doi:10.1136/jmg-2022-108898

Germline pathogenic variants (GPVs) in the cancer predisposition genes BRCA1, BRCA2, MLH1, MSH2, MSH6, BRIP1, PALB2, RAD51D and RAD51C are identified in approximately 15% of patients with ovarian cancer (OC). While there are clear guideline…

observational 2015
Journal of the National Cancer Institute ·doi:10.1093/jnci/djv214

BACKGROUND: Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, responsible for 13 000 deaths per year in the United States. Risk prediction based on identifying germline mutations in ovarian cancer susceptibility g…

nonrandomized-trial 2013
Journal of Clinical Oncology ·doi:10.1200/jco.2011.39.7638

PURPOSE: To establish the performance characteristics of annual transvaginal ultrasound and serum CA125 screening for women at high risk of ovarian/fallopian tube cancer (OC/FTC) and to investigate the impact of delayed screening interval a…

other 1997
other 1997
British journal of obstetrics and gynaecology ·doi:10.1111/j.1471-0528.1997.tb14366.x